Clinical Trials
2 trialsNCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT05115006 2022-06-30
A Study of Adjuvant Melanoma Stakeholder Treatment Preferences
Bristol-Myers Squibb
Completed